These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30052511)

  • 1. Mining human cancer datasets for kallikrein expression in cancer: the 'KLK-CANMAP' Shiny web tool.
    Wang C; Moya L; Clements JA; Nelson CC; Batra J
    Biol Chem; 2018 Sep; 399(9):983-995. PubMed ID: 30052511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.
    Avgeris M; Scorilas A
    Expert Opin Ther Targets; 2016 Jul; 20(7):801-18. PubMed ID: 26941073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated genomic characterization of the kallikrein gene locus in cancer.
    Girgis AH; Bui A; White NM; Yousef GM
    Anticancer Res; 2012 Mar; 32(3):957-63. PubMed ID: 22399617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic regulation of kallikrein-related peptidases: there is a whole new world out there.
    Pasic MD; Olkhov E; Bapat B; Yousef GM
    Biol Chem; 2012 Apr; 393(5):319-30. PubMed ID: 22505515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation profiles and regulatory cascades of the human kallikrein-related peptidases.
    Yoon H; Laxmikanthan G; Lee J; Blaber SI; Rodriguez A; Kogot JM; Scarisbrick IA; Blaber M
    J Biol Chem; 2007 Nov; 282(44):31852-64. PubMed ID: 17823117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer.
    White NM; Youssef YM; Fendler A; Stephan C; Jung K; Yousef GM
    Biol Chem; 2012 Apr; 393(5):379-89. PubMed ID: 22505520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of 15 human kallikreins in tissues and biological fluids.
    Shaw JL; Diamandis EP
    Clin Chem; 2007 Aug; 53(8):1423-32. PubMed ID: 17573418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the kallikrein-related peptidases for drug development.
    Sotiropoulou G; Pampalakis G
    Trends Pharmacol Sci; 2012 Dec; 33(12):623-34. PubMed ID: 23089221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictions for the future of kallikrein-related peptidases in molecular diagnostics.
    Scorilas A; Mavridis K
    Expert Rev Mol Diagn; 2014 Jul; 14(6):713-22. PubMed ID: 24927162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers.
    Emami N; Diamandis EP
    Clin Chem; 2008 Oct; 54(10):1600-7. PubMed ID: 18687738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mining for single nucleotide variants (SNVs) at the kallikrein locus with predicted functional consequences.
    Sukumar N; Scott E; Dimitromanolakis A; Misiak A; Prassas I; Diamandis EP; Konvalinka A
    Biol Chem; 2014 Sep; 395(9):1037-50. PubMed ID: 25153386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolutionary history of tissue kallikreins.
    Pavlopoulou A; Pampalakis G; Michalopoulos I; Sotiropoulou G
    PLoS One; 2010 Nov; 5(11):e13781. PubMed ID: 21072173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The kallikrein-related peptidase family: Dysregulation and functions during cancer progression.
    Kryza T; Silva ML; Loessner D; Heuzé-Vourc'h N; Clements JA
    Biochimie; 2016 Mar; 122():283-99. PubMed ID: 26343558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The GNA13-RhoA signaling axis suppresses expression of tumor protective Kallikreins.
    Teo CR; Casey PJ; Rasheed SA
    Cell Signal; 2016 Oct; 28(10):1479-88. PubMed ID: 27424208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kallikreins as microRNA targets: an in silico and experimental-based analysis.
    Chow TF; Crow M; Earle T; El-Said H; Diamandis EP; Yousef GM
    Biol Chem; 2008 Jun; 389(6):731-8. PubMed ID: 18627289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A computational analysis of the genetic and transcript diversity at the kallikrein locus.
    Lai J; An J; Srinivasan S; Clements JA; Batra J
    Biol Chem; 2016 Dec; 397(12):1307-1313. PubMed ID: 27289002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parallel overexpression of seven kallikrein genes in ovarian cancer.
    Yousef GM; Polymeris ME; Yacoub GM; Scorilas A; Soosaipillai A; Popalis C; Fracchioli S; Katsaros D; Diamandis EP
    Cancer Res; 2003 May; 63(9):2223-7. PubMed ID: 12727843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional roles of human kallikrein-related peptidases.
    Sotiropoulou G; Pampalakis G; Diamandis EP
    J Biol Chem; 2009 Nov; 284(48):32989-94. PubMed ID: 19819870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mass spectrometry based proteomics analyses in kallikrein-related peptidase research: implications for cancer research and therapy.
    Silva LM; Clements JA
    Expert Rev Proteomics; 2017 Dec; 14(12):1119-1130. PubMed ID: 29025353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic and other analyses to determine the functional consequences of deregulated kallikrein-related peptidase (KLK) expression in prostate and ovarian cancer.
    Fuhrman-Luck RA; Silva ML; Dong Y; Irving-Rodgers H; Stoll T; Hastie ML; Loessner D; Gorman JJ; Clements JA
    Proteomics Clin Appl; 2014 Jun; 8(5-6):403-15. PubMed ID: 24535680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.